No black box warning on record for Varubi

As of the latest FDA labeling reviewed, Varubi (ROLAPITANT) does not carry a black box warning. Standard warnings and precautions still apply — see the full Varubi medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS CYP2D6 Substrates : Rolapitant is a moderate inhibitor of CYP2D6 and significantly increases the plasma concentrations of CYP2D6 substrates for at least 28 days following single dose administration of VARUBI. Before starting VARUBI, consider if patients require: thioridazine or pimozide; if so, use an alternative antiemetic to VARUBI or an alternative to thioridazine or

No black box warning on record for Varubi

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS CYP2D6 Substrates : Rolapitant is a moderate inhibitor of CYP2D6 and significantly increases the plasma concentrations of CYP2D6 substrates for at least 28 days following single dose administration of VARUBI. Before starting VARUBI, consider if patients require: thioridazine or pimozide; if so, use an alternative antiemetic to VARUBI or an alternative to thioridazine or

Varubi Black Box Warning

No black box warning on record for Varubi

Other warnings & precautions

Varubi Black Box Warning

No black box warning on record for Varubi

Other warnings & precautions